Palisade Bio

PALI · NASDAQ

$1.43+$0.09 (+6.72%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.34

PALI analyst rating

BuyConsensus of 8 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy8
Hold0
Underperform0
Sell0

12-month price target · 12 analysts

Average $10.61 (+641.8% upside)

Low: $5.05
Now: $1.43
High: $26.25

Upgrades and downgrades

The latest rating actions, newest first

PALI analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Oct 13, 2026	Maintains	Buy	$7.00	32%
Raymond James	Oct 9, 2026	Initiates	Outperform	$6.00	33%
HC Wainwright & Co.	Sep 23, 2026	Maintains	Buy	$7.00	32%
Oppenheimer	Jul 23, 2026	Initiates	Outperform	$8.00	45%
Wolfe Research	Apr 9, 2026	Initiates	Outperform	$7.00	47%
HC Wainwright & Co.	Mar 26, 2026	Initiates	Buy	$7.00	32%
Stifel	Feb 25, 2026	Initiates	Buy	$5.00	59%
B. Riley Securities	Jan 9, 2026	Initiates	Buy	$7.00	23%
Clear Street	Dec 30, 2025	Initiates	Buy	$12.00	38%
Piper Sandler	Dec 29, 2025	Initiates	Overweight	$25.00	37%

The case for and against

Updated Oct 15, 2026

Bull case

Palisade Bio is attractive because PALI-2108 has shown a coherent early pharmacology story across tissue, biomarker, and endoscopic measures, including a 47.5% reduction in SES-CD, a 58.8% drop in fecal calprotectin, and 2/5 patients achieving endoscopic response and remission after 14 days. The drug also demonstrated about 7-fold higher ileal and colonic tissue concentrations than peak plasma levels, sustained PDE4 inhibition at 30 mg QD, and only mild adverse events with no serious discontinuations, supporting the plausibility of a well-tolerated chronic oral therapy. The clearance of ASCENTRA-CD, a cash balance of $125.2M as of mid-2026 funding operations through both Phase 2 primary readouts, and the upcoming 2H27 UC and 1Q28 Crohn’s catalysts further strengthen the fundamental case.

Bear case

Palisade Bio is viewed negatively because its valuation depends on a highly uncertain clinical-stage pipeline, with PALI-2108 assigned only a 40% probability of launch in UC and 30% in CD, and estimated launches not expected until 2030. The company’s DCF framework uses an 11% discount rate and 1% terminal growth rate to support an enterprise value of about $1.8B, but that figure remains fragile given the risk of insufficient efficacy, variable drug activation, and lingering PDE4 tolerability concerns. Its near-term financial cushion is limited, with end-3Q27 cash of roughly $101M against approximately 260M fully diluted shares, while trial delays, competitive IBD therapies, and possible medium- to long-term equity dilution further weaken the outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.